Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is ...

Stocks soared Wednesday as investors digested strong earnings reports from several large financial services companies and ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

The FTSE 100 ( ^FTSE) and European stocks were higher on Wednesday as traders digested news that UK inflation unexpectedly ...

Today is like a little taste of what the year could be like if everything goes just right. Inflation is cooler, bond yields ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Learn about the crucial role of the 340B drug pricing program for community-based health systems and the mounting challenges they face.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...